199 related articles for article (PubMed ID: 38287839)
1. Novel Targeted Therapies for Rheumatoid Arthritis Based on Intracellular Signalling and Immunometabolic Changes: A Narrative Review.
Rahmati M; Kwesiga MP; Lou J; Tan AL; McDermott MF
Front Biosci (Landmark Ed); 2024 Jan; 29(1):42. PubMed ID: 38287839
[TBL] [Abstract][Full Text] [Related]
2. Towards a stratified targeted approach with biologic treatments in rheumatoid arthritis: role of synovial pathobiology.
Astorri E; Nerviani A; Bombardieri M; Pitzalis C
Curr Pharm Des; 2015; 21(17):2216-24. PubMed ID: 25760296
[TBL] [Abstract][Full Text] [Related]
3. Rheumatoid arthritis: Recent advances on its etiology, role of cytokines and pharmacotherapy.
Alam J; Jantan I; Bukhari SNA
Biomed Pharmacother; 2017 Aug; 92():615-633. PubMed ID: 28582758
[TBL] [Abstract][Full Text] [Related]
4. The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis.
Hodge JA; Kawabata TT; Krishnaswami S; Clark JD; Telliez JB; Dowty ME; Menon S; Lamba M; Zwillich S
Clin Exp Rheumatol; 2016; 34(2):318-28. PubMed ID: 26966791
[TBL] [Abstract][Full Text] [Related]
5. Biologic agents in rheumatoid arthritis: an update for managed care professionals.
Agarwal SK
J Manag Care Pharm; 2011; 17(9 Suppl B):S14-8. PubMed ID: 22073935
[TBL] [Abstract][Full Text] [Related]
6. Treatment of rheumatoid arthritis: Unraveling the conundrum.
Zampeli E; Vlachoyiannopoulos PG; Tzioufas AG
J Autoimmun; 2015 Dec; 65():1-18. PubMed ID: 26515757
[TBL] [Abstract][Full Text] [Related]
7. Signaling pathways in rheumatoid arthritis: implications for targeted therapy.
Ding Q; Hu W; Wang R; Yang Q; Zhu M; Li M; Cai J; Rose P; Mao J; Zhu YZ
Signal Transduct Target Ther; 2023 Feb; 8(1):68. PubMed ID: 36797236
[TBL] [Abstract][Full Text] [Related]
8. Metabolic Control of Autoimmunity and Tissue Inflammation in Rheumatoid Arthritis.
Qiu J; Wu B; Goodman SB; Berry GJ; Goronzy JJ; Weyand CM
Front Immunol; 2021; 12():652771. PubMed ID: 33868292
[TBL] [Abstract][Full Text] [Related]
9. [The immunologic homunculus in rheumatoid arthritis. A new viewpoint of immunopathogenesis in rheumatoid arthritis and therapeutic consequences].
Bläss S; Engel JM; Burmester GR
Z Rheumatol; 2001 Feb; 60(1):1-16. PubMed ID: 11263010
[TBL] [Abstract][Full Text] [Related]
10. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
Brown S; Everett CC; Naraghi K; Davies C; Dawkins B; Hulme C; McCabe C; Pavitt S; Emery P; Sharples L; Buch MH
Health Technol Assess; 2018 Jun; 22(34):1-280. PubMed ID: 29900829
[TBL] [Abstract][Full Text] [Related]
11. Delineation of the distinct inflammatory signaling roles of TAK1 and JAK1/3 in the CIA model of rheumatoid arthritis.
Freeze R; Yang KW; Haystead T; Hughes P; Scarneo S
Pharmacol Res Perspect; 2023 Aug; 11(4):e01124. PubMed ID: 37564034
[TBL] [Abstract][Full Text] [Related]
12. Natural products action on pathogenic cues in autoimmunity: Efficacy in systemic lupus erythematosus and rheumatoid arthritis as compared to classical treatments.
Cao F; Cheng MH; Hu LQ; Shen HH; Tao JH; Li XM; Pan HF; Gao J
Pharmacol Res; 2020 Oct; 160():105054. PubMed ID: 32645358
[TBL] [Abstract][Full Text] [Related]
13. Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection.
Biggioggero M; Crotti C; Becciolini A; Favalli EG
Drug Des Devel Ther; 2019; 13():57-70. PubMed ID: 30587928
[TBL] [Abstract][Full Text] [Related]
14. Innate immunity drives pathogenesis of rheumatoid arthritis.
Edilova MI; Akram A; Abdul-Sater AA
Biomed J; 2021 Apr; 44(2):172-182. PubMed ID: 32798211
[TBL] [Abstract][Full Text] [Related]
15. The effect of targeted rheumatoid arthritis therapies on anti-citrullinated protein autoantibody levels and B cell responses.
Modi S; Soejima M; Levesque MC
Clin Exp Immunol; 2013 Jul; 173(1):8-17. PubMed ID: 23607804
[TBL] [Abstract][Full Text] [Related]
16. Novel Therapeutic Approaches in Rheumatoid Arthritis: Role of Janus Kinases Inhibitors.
Rivellese F; Lobasso A; Barbieri L; Liccardo B; de Paulis A; Rossi FW
Curr Med Chem; 2019; 26(16):2823-2843. PubMed ID: 29424301
[TBL] [Abstract][Full Text] [Related]
17. Novel therapies for rheumatoid arthritis.
Tremoulet AH; Albani S
Expert Opin Investig Drugs; 2006 Nov; 15(11):1427-41. PubMed ID: 17040201
[TBL] [Abstract][Full Text] [Related]
18. Rheumatoid arthritis: Biological therapy other than anti-TNF.
Rossi D; Modena V; Sciascia S; Roccatello D
Int Immunopharmacol; 2015 Aug; 27(2):185-8. PubMed ID: 25840282
[TBL] [Abstract][Full Text] [Related]
19. Metabolic reprogramming as a key regulator in the pathogenesis of rheumatoid arthritis.
Cai WW; Yu Y; Zong SY; Wei F
Inflamm Res; 2020 Nov; 69(11):1087-1101. PubMed ID: 32797249
[TBL] [Abstract][Full Text] [Related]
20. Futuristic Novel Therapeutic Approaches in the Treatment of Rheumatoid Arthritis.
Rai V; Patel N; Mammen SR; Chaudhary SM; Arshad S; Munazzam SW
Cureus; 2023 Nov; 15(11):e49738. PubMed ID: 38161868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
